AXT (AXTI) has had the highest return since October 30, 2025 by a mid-cap US stock, returning 718.2%.
| ASSET | % RETURN |
|---|---|
AXT (AXTI) | 718.21% |
Erasca (ERAS) | 685.96% |
Sellas Life Sciences (SLS) | 628.95% |
Alumis (ALMS) | 466.24% |
Anterix (ATEX) | 446.18% |
Ichor (ICHR) | 318.67% |
Maase (MAAS) | 316.34% |
Immunitybio (IBRX) | 296.64% |
Veradermics (MANE) | 281.59% |
Ultra Clean (UCTT) | 278.11% |
Tango Therapeutics (TNGX) | 276.25% |
Bandwidth (BAND) | 274.24% |
Butterfly Network (BFLY) | 265.71% |
Spyre Therapeutics (SYRE) | 264.14% |
PACS (PACS) | 262.21% |
Liquidia Technologies (LQDA) | 254.42% |
Applied Opt (AAOI) | 250.68% |
Definium Therapeutics (DFTX) | 239.92% |
Iridium Communications (IRDM) | 222.82% |
ChronoScale (CHRN) | 214.1% |
Twist Bioscience (TWST) | 210.22% |
Oruka Therapeutics (ORKA) | 209.18% |
Kulicke and Soffa Industries (KLIC) | 207.41% |
10X Genomics (TXG) | 205.72% |
Hycroft Mining (HYMC) | 204.77% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.